MoonLake Immunotherapeutics
MLTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821586
In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 6 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in MoonLake Immunotherapeutics as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +1 vs. Q2 2022
- Shares held
- 36.9M
- +385.8K (+1.1%) vs. Q2 2022
- Total value
- $291.4M
- +$101.3M (+53.3%) vs. Q2 2022
- New holders
- 5
- 4 more added
- Sold out
- 4
- 8 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MLTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 172 | $1.43B |
| Q1 2026 | 147 | $1.17B |
| Q4 2025 | 130 | $742.9M |
| Q3 2025 | 134 | $269.7M |
| Q2 2025 | 130 | $2.77B |
| Q1 2025 | 136 | $2.34B |
| Q4 2024 | 116 | $3.43B |
| Q3 2024 | 109 | $3.14B |
| Q2 2024 | 111 | $2.67B |
| Q1 2024 | 114 | $2.99B |
| Q4 2023 | 125 | $3.53B |
| Q3 2023 | 118 | $3.21B |
| Q2 2023 | 83 | $2.86B |
| Q1 2023 | 43 | $843.2M |
| Q4 2022 | 33 | $396.4M |
| Q3 2022 | 24 | $291.4M |
| Q2 2022 | 23 | $190.1M |
| Q1 2022 | 27 | $123.4M |
| Q4 2021 | 45 | $112.8M |
| Q3 2021 | 43 | $111.1M |
| Q2 2021 | 46 | $115.8M |
| Q1 2021 | 42 | $108.9M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding MoonLake Immunotherapeutics; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BVF Inc | 21,751,284 | $173.1M | 7.15% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 6,065,001 | $47.1M | 3.31% | 00.0% | Unchanged |
| Citadel Advisors LLC | 2,685,937 | $21.4M | 0.03% | −16,724−0.6% | Reduced |
| TCG Crossover Management, LLC | 1,000,000 | $7.76M | 2.33% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 869,388 | $6.92M | 0.00% | −1,136−0.1% | Reduced |
| FMR LLC | 819,177 | $6.52M | 0.00% | −374,113−31.4% | Reduced |
| BlackRock Inc. | 741,832 | $5.76M | 0.00% | −740.0% | Reduced |
| RTW Investments, LP | 500,000 | $3.88M | 0.09% | 00.0% | Unchanged |
| Great Point Partners LLC | 492,000 | $3.82M | 0.92% | +60,000+13.9% | Added |
| Point72 Asset Management, L.P. | 335,000 | $2.60M | 0.01% | +335,000 | New |
| Tekla Capital Management LLC | 300,000 | $2.39M | 0.10% | +300,000 | New |
| Ghost Tree Capital, LLC | 300,000 | $2.33M | 0.95% | 00.0% | Unchanged |
| Tang Capital Management LLC | 259,054 | $2.01M | 0.25% | −59,989−18.8% | Reduced |
| Monashee Investment Management LLC | 191,945 | $1.49M | 0.55% | −8,055−4.0% | Reduced |
| Citigroup Inc | 159,087 | $1.27M | 0.00% | 00.0% | Unchanged |
| Balyasny Asset Management LLC | 99,874 | $795.0K | 0.00% | +99,874 | New |
| UBS Group AG | 75,664 | $587.0K | 0.00% | +2,004+2.7% | Added |
| TD Asset Management Inc | 67,312 | $538.0K | 0.00% | +38,346+132.4% | Added |
| Jefferies Group LLC | 67,654 | $525.0K | 0.02% | +67,654 | New |
| Meridian Wealth Management, LLC | 27,000 | $210.0K | 0.02% | 00.0% | Unchanged |
| Alps Advisors Inc | 20,144 | $160.0K | 0.00% | −11,116−35.6% | Reduced |
| Barclays PLC | 15,184 | $118.0K | 0.00% | +101+0.7% | Added |
| Goldman Sachs Group Inc | 10,210 | $79.0K | 0.00% | −1,575−13.4% | Reduced |
| Morgan Stanley | 3,100 | $24.0K | 0.00% | +3,100 | New |
| Millennium Management LLC | 0 | $0 | 0.00% | −28,090−100.0% | Sold out |
| Cowen and Company, LLC | 0 | $0 | 0.00% | −16,173−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −3,195−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −25−100.0% | Sold out |